Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study to Examine the Characteristics of HIV Decay Following Introduction of Combination Antiretroviral Therapy Including Raltegravir During Primary and Chronic HIV Infection

Next Previous
Trial Profile

An Open Label Study to Examine the Characteristics of HIV Decay Following Introduction of Combination Antiretroviral Therapy Including Raltegravir During Primary and Chronic HIV Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms PINT

Most Recent Events

  • 01 Apr 2011 Additional lead centre (Kirby Institute) added as reported by ClinicalTrials.gov.
  • 07 Apr 2009 Planned end date changed from 1 Sep 2010 to 1 Nov 2011 as reported by ClinicalTrials.gov.
  • 07 Apr 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top